Clinical Profile, Humanistic and Economic Burden of Paroxysmal Nocturnal Hemoglobinuria in Patients Treated With C5 Inhibitors
Despite C5i treatment, a notable proportion of patients remained anemic and reported impaired quality of life, indicating the need for novel, efficacious therapies.
Authors
- M. Balp
- Josefin Snellman
- Olivier Somenzi
- Markus P. Radsak (ORCID: https://orcid.org/0000-0002-3991-5721)
- S. Gandhi
- A. Wiyani
- Yasutaka Ueda (ORCID: https://orcid.org/0000-0003-1562-1013)
- Yasmin Taylor (ORCID: https://orcid.org/0000-0003-4454-5013)
- Alice Simons
- Jens Peter Panse
Institutions
- Novartis (Switzerland) (CH)
- Adelphi Group (United Kingdom) (GB)
- King's College Hospital NHS Foundation Trust (GB)
- Novartis (United Kingdom) (GB)
- Klinik Donaustauf (DE)
- King's College Hospital (GB)
- RWTH Aachen University (DE)
- The University of Osaka (JP)
Publication Details
- Journal
- eJHaem
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/jha2.70248
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00